Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Cash from Financing Activities (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Cash from Financing Activities for 3 consecutive years, with -$23550.0 as the latest value for Q4 2024.

  • Quarterly Cash from Financing Activities changed N/A to -$23550.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$4.0 million through Dec 2024, down 7.72% year-over-year, with the annual reading at $63.5 million for FY2025, 1306.02% up from the prior year.
  • Cash from Financing Activities hit -$23550.0 in Q4 2024 for Pasithea Therapeutics, up from -$3.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $34.2 million in Q4 2021 to a low of -$3.9 million in Q3 2023.
  • Historically, Cash from Financing Activities has averaged $7.5 million across 3 years, with a median of $264103.0 in 2023.